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Abstract
Inconsistency in outcome parameters for delayed cerebral ischemia (DCI) makes it difficult to compare results between mouse
studies, in the same way inconsistency in outcome parameters in human studies has for long obstructed adequate comparison.
The absence of an established definitionmay in part be responsible for the failed translational results. The present article proposes
a standardized definition for DCI in experimental mouse models, which can be used as outcomemeasure in future animal studies.
We used a consensus-building approach to propose a definition for “experimental secondary ischemia” (ESI) in experimental
mouse subarachnoid hemorrhage that can be used as an outcome measure in preclinical studies. We propose that the outcome
measure should be as follows: occurrence of focal neurological impairment or a general neurological impairment compared with
a control group and that neurological impairment should occur secondarily following subarachnoid hemorrhage (SAH) induction
compared with an initial assessment following SAH induction. ESI should not be used if the condition can be explained by
general anesthesia or if other means of assessments sufficiently explain function impairment. If neurological impairment cannot
reliably be evaluated, due to scientific setup. Verification of a significant secondary impairment of the cerebral perfusion
compared with a control group is mandatory. This requires longitudinal examination in the same animal. The primary aim is
that ESI should be distinguished from intervention-related ischemia or neurological deficits, in order establish a uniform defi-
nition for experimental SAH in mice that is in alignment with outcome measures in human studies.
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Background
Early brain injury (EBI) and delayed cerebral ischemia (DCI)
are the two main determinants for survivors’ outcome after
aneurysmal subarachnoid hemorrhage (aSAH). DCI and EBI
are well defined for clinical use and have been studied exten-
sively in order to treat EBI-related symptoms, determine the
prognosis of aSAH patients, reduce the incidence of DCI, and
improve functional outcome after aSAH. Mice were the latest
species that was introduced into experimental SAH research in
1999 [20]. But the number of studies in mice has steadily
increased during the last two decades and has—together with
rat and rabbit models—become one of the most commonly
used species in preclinical SAH research [21]. Various
pharmaceutics showed promising results in in vivo animal
studies. However, despite the high number of animal studies,
different therapeutic approaches, and numerous analyzed
pharmaceutics, standard therapies of DCI have barely
changed and oral nimodipine remains the only drug to im-
prove neurological outcome in aSAH patients.
In response to unsatisfactory translational results, guide-
lines for a standardized reporting of animal experiment have
been implemented and meta-analysis of existing data has been
proposed in order to detect for sources of bias and better esti-
mate effect sizes [13, 14, 19, 32]. Despite a reduction of the
species used in SAH animal models, diversity of the experi-
mental setups has not decreased over time. The variety of
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experimental setups including the model (single-, double-
injection model, amount of blood injected etc.) and the lack
of standardization of models was considered as one reason for
the disappointing translation of basic SAH research [18].
Translational difficulties might also stem from interspecies
differences such as the clearance rate of subarachnoid blood
or the amount of collaterals in the animal brain [17, 23]. As a
result, pathophysiological processes important in humans
might not have a similar relevance in an experimental setting.
Moreover, DCI may have also been missed due to a lack of
longitudinal observation or clear definition for DCI in exper-
imental models [12]. This inconsistency in outcome parame-
ters makes it difficult to compare results between studies, in
the same way inconsistency in outcome parameters in human
studies has for long obstructed adequate comparison of results
[37]. The absence of established definition for DCI may thus
in part be responsible for failed translational results [12]. The
present article aims to propose standardized definitions for
DCI in experimental mouse models for aSAH that can be used
as outcome measures in future animal studies.
Methods
We used a consensus-building approach analog to the method
used by Vergouwen et al. [37]. At the start of the study, two
authors (M.K. and J.V.L.) developed the idea to propose stan-
dardized definitions for DCI in experimental models for SAH.
Both authors subsequently proposed a draft manuscript con-
taining definitions of DCI for mouse models in experimental
SAH research.We identified and contacted a multidisciplinary
group of experts in the field of experimental SAH research
and invited them to help shape the standardized definitions for
DCI in mouse models for experimental SAH. The draft man-
uscript was sent to all coauthors. We implemented the sugges-
tions of the coauthors and send the manuscript back to all
coauthors.M.K. and J.V.L. mediated this process and repeated
it three times until a consensus was reached between all
authors.
Considerations for the Definition
Delayed Cerebral Ischemia
The definition of DCI in a clinical setting has been described
by Vergouwen et al. as:
“The occurrence of focal neurological impairment (such as
hemiparesis, aphasia, apraxia, hemianopia, or neglect), or a
decrease of at least 2 points on the Glasgow Coma Scale
(either on the total score or on one of its individual compo-
nents [eye, motor on either side, verbal]). This should last for
at least 1 hour, is not apparent immediately after aneurysm
occlusion, and cannot be attributed to other causes by means
of clinical assessment, CT or MRI scanning of the brain, and
appropriate laboratory studies.” [37].
This definition is not applicable in experimental SAH due
to multiple reasons.
(1) The outcome parameters in experimental mouse models
should mimic their human counterparts [31, 37]. But
there are two main reasons why we cannot apply this
definition directly to experimental SAH in mice.
Excluding other possible causes of neurological impair-
ment with CT or MRI scanning of the brain and appro-
priate laboratory testing is not feasible due to logistical
and practical reasons.
(2) DCI in humans usually does not occur before the third
day after ictus. In experimental SAH, the phenomenon of
DCI can present itself much earlier, for mice as early as
6 h after induction of SAH [10, 11]. Due to animal wel-
fare and regulatory reasons, researchers always induce
experimental SAH under general anesthesia. In our ex-
perience, adequate neurological assessment and differen-
tiation between SAH- and anesthesia-induced neurolog-
ical impairment is not possible until 12 to 24 h after SAH
induction [10]. Because of the sedation, a definition
based purely on clinical features might result in either
over- or underestimation of the true incidence of DCI,
since the mice awake from anesthesia within the DCI
period, and differentiation between clinical deterioration
due to DCI and EBI is challenging.
(3) Many studies try to model DCI following experimental
SAH. However, as stated above, it remains questionable
if and to what extend animal and—in particular—mouse
models resemble DCI and if DCI exists following exper-
imental SAH. Therefore, in our view, the term “delayed
cerebral ischemia/DCI” should not be used in connection
with an experimental setup. Instead, we propose to use
the term “experimental secondary ischemia or ESI” for
those pathophysiological and clinical reactions which
should resemble DCI in experimental SAH and which
occur secondary following early brain injury.
What Kinds of Measures Are Essential for a Definition
of ESI in Mice?
(1) Neurological testing for small ischemia in mice is diffi-
cult due to the poor sensitivity of neurocognitive testing.
Mice have a total brain volume of about 500 mm3 and
may have 10–30-mm3 infarctions by a total brain volume
without any detectable motor impairment [16]. This may
contribute to the difficulties faced in SAH research and
standard of reporting. Researchers may also miss smaller
cortical cerebral ischemia as they are mostly not
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clinically manifested in mice. A good example for this is
the distal pMCAO mouse model [24, 25, 30]. Also, def-
icits caused by SAH induction itself may be severe
enough to mask secondary neurological deficits.
However, as clinical deterioration is an integral part of
the DCI definition, secondary focal or global neurologi-
cal impairment should be part of the ESI definition.
(2) The term “delayed cerebral ischemia” implies that ische-
mia is responsible for focal and neurological impairment
in aSAH patients. Since not all SAH models may effec-
tively detect neurological impairment, detection of any
kind of significant changes in cerebral perfusion or in-
farction should be an integral part of a definition of ESI.
If neurological examination cannot reliably be performed
due to the scientific setup, it is critical to ascertain wheth-
er any ischemia develops in a delayed manner, which
may qualify for DCI.
(3) Although not explicitly stated in the clinical definition by
Vergouwen et al., the term DCI refers to a secondary clin-
ical deterioration [37]. DCI should be separated from ische-
mia caused by perfusion impairment closely following an-
eurysm rupture and from intervention associated cerebral
ischemia: Aneurysm rupture typically induces a steep in-
crease of the intracranial pressure (ICP) and a massive de-
crease of the cerebral perfusion and may subsequently lead
to disruption of neuronal signaling and to a generalized or
focal hypoxic injury [35]. In experimental SAH, perfusion
impairment associated with SAH induction and related to
interventions should clearly be separated from DCI. Again,
primary (e.g., EBI or intervention-related ischemia) and
secondary neurological impairment cannot reliably be dis-
tinguished in mouse models due to general anesthesia and
earlier onset of DCI. However, a secondary—and not a
primary—impairment of neurological function and cerebral
perfusion is an important feature of DCI and necessary to
differentiate EBI and DCI. We therefore recommend that
neurological impairment or impairment of the cerebral per-
fusion should occur secondarily after SAH induction and
requires longitudinal assessment of the same animal [10,
11]. Initial assessment should document deficits 12 to
24 h after SAH induction and serial exams should follow
in order to detect any exacerbation [10].
(4) As in humans, ESI should ideally be a diagnosis per
exclusionem. However, since other factors such as ede-
ma, hydrocephalus, metabolic causes, or iatrogenic le-
sions caused by SAH induction are difficult to distin-
guish, it is inherently difficult to know for sure whether
clinical deteriorations can be truly attributed to ESI. This
introduces a possible source of overestimation. Only in
the case that other assessments (e.g., imaging, laboratory,
or autopsy results) or induction of SAH itself sufficiently
explains focal or global function impairment must ESI
not be taken in to account.
(5) Clinical and pathophysiological responses following
aSAH should be compared with at least one adequate
control group (ideally a sham and saline control group).
By using suitable controls, such as a control saline injec-
tions, effects of subarachnoid blood can be differentiated
from other effects caused, e.g., by injection or temporary
filament occlusion. As control groups are—of course—
not part of the clinical DCI definition, we consider ade-
quate control group not as a part of definition of ESI but
of good scientific practice.
Neurological Impairment
Clinical examination for stroke and aSAH patients is more or
less standardized [5, 8, 29, 33]. A standardized neurological
evaluation is the prerequisite for clinical grading and predic-
tion of clinical outcome [5, 8, 33].Various versions of scores
for neurological assessment in mice are used, including a
Modified Mouse Coma Scale, however no common scoring
system for injury severity that has been widely adopted for
animals based on a brief neurological examination, like the
GlasgowComa Scale in human patients with aSAH [1–4, 6, 7,
10, 26, 28, 36]. Neurological assessment of mice in experi-
mental SAH derives from other species and stroke research [4,
7, 28]. Next to behavioral tests, some well-established motor
function tests, such as the tape removal test or the rotarod test,
are used in experimental mouse SAH [9, 15, 22, 26, 34].
However, scores for neurological evaluation assessing motor
and sensory function are more common: These scores derive
from rat models in translational stroke research and are
adapted for their use in experimental mouse models.
Recommendations for a basic neurological assessment of
mice in experimental SAH might increase comparability be-
tween studies, but are beyond the scope of the present manu-
script. We recommend using an established score for a basic
neurological assessment, which allows for standardized neu-
rological assessment and comparability between different ex-
perimental groups.
Assessment of Cerebral Perfusion Impairment
and Cerebral Infarction
As previously stated, detection of any kind of cerebral infarc-
tion and/or cerebral perfusion deficit should be an integral part
of a definition of experimental secondary ischemia. However,
there is a widespread of substitutes and definitions for vaso-
spasms and perfusion impairment throughout the literature on
experimental mouse SAH. Standardization of assessing cere-
bral vasospasms and perfusion impairment is beyond the
scope of this manuscript. However, there is a disconnection
between large artery vasospasms and clinical outcome in
humans. In our view, evaluation of cerebral perfusion
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impairment or detection of infarctions should therefore be
preferred to detection of cerebral vasospasms. Ideally, cerebral
perfusion would be measured without sedation or anesthesia
but due to animal welfare and regulatory reasons, the initial
perfusion measurement during SAH induction will always
need to be performed under general anesthesia. Moreover, as
disconnection between large artery vasospasms and clinical
outcome in humans might be one reason for the translational
problem, assessment of cerebral perfusion should ideally not
only focus on verification of large artery vasospasms but also
quantify the cerebral perfusion itself. Neuroimaging and brain
perfusion assessments should ideally be used to discern injury
early after SAH induction and serve as comparison for follow-
up to identify secondary ischemia. Clearly, neuroimaging in
experimental SAH is not routinely used and its impracticality
makes it rather not advisable.
Proposed Standardized Definitions
for “Experimental secondary Ischemia”
in Experimental Mouse Models
for Aneurysmal Subarachnoid Hemorrhage
Proposed Definition of ESI in Experimental Mouse
SAH
(1) Occurrence of focal neurological impairment (as
assessed by standard score to assess neurologic perfor-
mance in mice after SAH), or a general neurological
impairment (lethargic or comatose condition) compared
with a control group
and
(2) Neurological impairment should occur secondarily fol-
lowing SAH induction compared with the first possible
assessment following SAH induction
and
(3) ESI should not be taken in to account if the condition can
be explained by general anesthesia or if other means of
assessments (confirmed by autopsy results) sufficiently
explain focal or global function impairment
or
(4) If 2 does not apply, due to scientific setup. Verification of
a significant secondary impairment of the cerebral perfu-
sion (e.g., cerebral hypoperfusion of infarction demon-
strated by follow-up imaging or histopathology) com-
pared with a control group is mandatory. This requires
longitudinal examination in the same animal.
Implications and Generalization of ESI
to Other Species
A recent literature review suggests that animal models, with
the exception of primates, do not fully recapitulate the pro-
gression of DCI in humans [27]. Especially delayed/
secondary neurological deficits were not detected in most
mice, dog, rat, or rabbit models, but the incidence in primate
models was similar to the incidence of delayed cerebral ische-
mia in humans. The majority of animal models could not
faithfully reproduce a pathophysiological situation, which
was severe enough to cause infarction, regardless of the meth-
od and species [27]. Similarly, the mean overall mortality rate
in experimental mouse models of aSAH is significantly lower
than the reported human case fatality [11].
It could be argued that therefore is a need for the develop-
ment of new animal models that more faithfully resemble the
human condition for both case fatality and DCI. The elastase-
hypertension model is one such an attempt to more faithfully
reproduce the human condition. However, this model is not
without its own problems. The unpredictability of aneurysm
rupture and elastase-induced changes to the arterial wall may
complicate the study of DCI in this model. Also, other than
that the mechanism of rupture seems to be more similar, there
are no definitive indications that such a model will be able to
better recapitulate the progression of DCI in humans.
In parallel, it might be useful to better understand what
exactly happens in our models. It is therefore important to
establish a uniform terminology in order to address the incon-
sistency in outcome parameters, which has complicated ade-
quate comparison of results between studies. Certain models
may turn out to more effectively reproduce ESI than others.
Although primarily aimed at the mouse model, the same def-
inition of ESI might be applied to other animal models of
experimental SAH.
The present definition dispenses a timely definition of DCI
and EBI. As previously mentioned, the timely classification
between EBI and DCI is difficult in experimental SAH, has
not been really helpful in the clinical setting, and has very
limited value in the experimental setting. Moreover, it remains
questionable if EBI and DCI are pathophysiologically linked
and if there is a unifying link between EBI and DCI in either
human or experimental SAH. A division in primary and sec-
ondary ischemia might be better transferable. This terminolo-
gy links primary ischemia to the perfusion deficits and hyp-
oxia directly caused by the pathophysiological changes imme-
diately following aneurysm ruptures and secondary ischemia
to all brain perfusion impairments following (partial) recovery
of primary ischemia. From our impression, primary ischemia
seems to be highly comparable between different species and
involves similar pathophysiological mechanisms including se-
vere cerebral perfusion impairment in parallel to a massive
increase of the ICP and a disruption of neuronal signaling.
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In contrast, occurrence, time-point, and mechanisms of sec-
ondary ischemia seem to be much more heterogeneous and
likely significantly vary between different species.
It remains to be tested if therapeutic interventions that ef-
fectively reduce the occurrence of ESI are more predictive of
translational results in humans. We recognize that the estab-
lishment of a definition for ESI requires a broad international
consensus and that trying to introduce a clinically relevant
outcome measure is challenging. However, we hope that ESI
aids the clinical relevance and predictive value of experimen-
tal mouse models of SAH for DCI. Future efforts should sys-
tematically investigate to what extent aSAH animal models
resemble the human condition and how parameters such as
the experimental model, animal species, anesthesia, or the
genetic background affect EBI- and DCI-related pathophysi-
ological responses.
Conclusion
We propose a standardized definition for experimental sec-
ondary ischemia (ESI) in experimental mouse SAH analog
to the DCI in humans which can be used for future experi-
mental SAH research in mouse models. The primary aim is
that ESI should be distinguished from intervention-related is-
chemia or neurological deficits.
We hope to spark a broader discussion about the compara-
bility of definitions used in clinical practice and in a laboratory
setup. A common language (standardized definitions) of ad-
ditional core characteristics and endpoints of preclinical SAH
research, based on common data elements for data collection
and reporting, will be important to improve quality of SAH
research and translational success.
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